Cardiology · Heart FailureTrial Updateclinicalmid-term

NHLBI Launches MAP-HEART Study to Analyze Heart Failure Phenotypes

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/30/2026, 6:31:32 AM

Assessment confidence: 80% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The MAP-HEART study is significant as it aims to identify new biomarkers and therapeutic targets in heart failure, which could reshape treatment strategies. Pharma companies should stay informed on the study's findings to leverage potential insights for drug development. Regulatory context from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) supports the near-term read. Assessment grounded in 9 ranked evidence items (7 high-relevance).

Strategic Assessment

Pharma findings for potential new targets or insights that could inform drug development in heart failure. The strongest clinical anchor is Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany (ClinicalTrials.gov), sub-indication match (cardiology); sponsor/company relevance (astrazeneca). In cardiology, 3 regulatory and 1 competitive items passed relevance filtering for NHLBI.

Competitive Pressure

The most relevant competitive pressure comes from Study on Predicting Sudden Cardiac Death Risk in Patients with Moderate LVEF (Humanexa Signals) — sub-indication match (cardiology). This study may uncover new biomarkers or therapeutic targets, potentially influencing treatment strategies in heart failure management.

Regulatory Outlook

Regulatory risk is concentrated around Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension (MHRA). Sub-indication match (cardiology); Regulatory pathway relevance (indication). Relevant agencies in corpus: MHRA, FDA. Discoveries from the study may influence regulatory pathways for new heart failure therapies, potentially affecting approval timelines and labeling.

Key Risks

Elevated medium regulatory exposure for NHLBI could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) could weigh on NHLBI through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany) could weigh on NHLBI through efficacy or safety read-through uncertainty if follow-through weakens.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on NHLBI through agency review timelines and labeling constraints if follow-through weakens.
Competitive risk from Humanexa Signals (Study on Predicting Sudden Cardiac Death Risk in Patients with Moderate LVEF) could weigh on NHLBI through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

New insights from this study could lead to the development of innovative therapies, impacting market share and revenue for companies involved in heart failure treatments.
Upside for NHLBI may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Pharma findings for potential new targets or insights that could inform drug development in heart failure.

What Would Change This Assessment

This becomes more urgent if Results from the sample analysis and any subsequent publications that may reveal new insights into heart failure mechanisms.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology); Regulatory pathway relevance (indication)
FDA document
View source
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
MHRA launches AI sandbox to accelerate medicines development and improve safety
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF)
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPT
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Study on Predicting Sudden Cardiac Death Risk in Patients with Moderate LVEF
Humanexa Signalshigh relevance
Sub-indication match (cardiology)

High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

NHLBI
heart failure patients
pharmaceutical companies

Commercial impact

medium

New insights from this study could lead to the development of innovative therapies, impacting market share and revenue for companies involved in heart failure treatments.

Regulatory impact

medium

Discoveries from the study may influence regulatory pathways for new heart failure therapies, potentially affecting approval timelines and labeling.

What to watch

Results from the sample analysis and any subsequent publications that may reveal new insights into heart failure mechanisms.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.